The Tumor-Agnostic Developer’s Toolkit
Eight Criteria To Consider For Next-Generation Agnostic Drugs
In Vivo has identified the pipeline of next-generation tumor-agnostic drugs and created a guide to the ideal trial strategies for these potentially transformative candidates.
